ANGLE : Appointment of Dr Jan Groen as NED

For immediate release

1 November 2018

ANGLE plc ('the Company')

Appointment of Dr Jan Groen as Non-Executive Director

Brings significant expertise in commercialising cancer diagnostics

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointment of Dr Jan Groen as a Non-Executive Director of the Company effective 1 November 2018.

Dr Groen has extensive Board and Executive level experience in cancer diagnostics. He is currently President and CEO of MDxHealth, a Euronext listed molecular diagnostic company that develops and commercialises cancer diagnostic tests to assist physicians in the detection and treatment of urological and other cancers, a position he has held since 2010. During his time at MDxHealth, he has helped to grow revenues from c. US$4 million in 2012 to c. US$41 million in 2017, with a total cumulative revenue of over US$100 million by 2017, and raised US$80 million in equity financing. He has established a CLIA service laboratory in the United States, an ISO service laboratory in Europe and built a team of over 220 staff to sell and undertake their prostate and other cancer diagnostic tests.

Prior to MDx Health, Dr Groen was President of US Operations and Global Chief Operating Officer at Agendia, a world leader in the rapidly evolving field of cancer molecular diagnostics using tumor gene expression, including tests that predict the risk of breast cancer recurrence (MammaPrint) and to identify the origin of cancer of unknown primary.

Dr Groen has significant expertise in new product development, including development of more than 25 CE marked and FDA cleared diagnostic products and lab-developed tests in Europe and the USA, and has successfully launched and commercialised several such tests.

Dr Groen also holds a Non-Executive Board position at SPL Medical, a private Dutch company combining an innovative contrast agent (Combidex®) with magnetic resonance imaging (MRI), with the ability to detect small lymph node metastases. He was previously a board member of MyCartis, a private Belgium company developing a Dynamic Multi-Analyte Technology (DMAT®) for immuno-diagnostics and IBL International, a VC backed company based in Germany manufacturing and selling immune-diagnostic assay which was sold to Tecan in July 2014.

ANGLE Founder and Chief Executive, Andrew Newland, commented:

'I am delighted to welcome Jan Groen to the Board of ANGLE. He has a proven track record of successfully commercialising cancer diagnostics in the USA and Europe. His knowledge and experience of this market will be of significant value as we progress the commercialisation of our Parsortix^TM liquid biopsy solution.'

The following information regarding Jan Groen, aged 58, is disclosed under Schedule 2(g) of the AIM Rules for Companies:

Current directorships and/or partnerships			Former directorships and/or partnerships(within the last five years)
MDxHealth S.A.			MyCartis NV
SPL Medical B.V.			IBL International
DxOrange B.V.

There are no further disclosures to be made under Schedule 2g of the AIM Rules for Companies.

For further information ANGLE:

ANGLE plc	[phone]
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker) Corporate Finance - Carl Holmes, Simon Hicks, Max Bullen-Smith ECM - Alice Lane	[phone]
WG Partners (Joint Broker) Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee	[phone]
FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert Matthew Ventimiglia (US)	[phone] [phone]

For Frequently Used Terms, please see the Company's website onhttp://www.angleplc.com/the-parsortix-system/glossary/

This announcement contains inside information.

Notes for editors

About ANGLE plcwww.angleplc.com

ANGLE is a world leading liquid biopsy company with sample to answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE's cell separation technology is called the Parsortix^TM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. The Parsortix system has a CE Mark in Europe for the indicated use and FDA clearance is in process for the United States.

ANGLE's analysis technology for proteins and nucleic acids of all types is called Ziplex^® and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The Ziplex system is ideal for measuring gene expression and other markers directly from Parsortix harvests.

ANGLE's proprietary technologies can be combined to provide automated, sample to answer results in both centralised laboratory and point of use cartridge formats.

Furthermore, ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available herehttp://www.angleplc.com/the-company/collaborators/